Business ❯ Healthcare ❯ Biotechnology

Drug Discovery

AI in Healthcare Clinical Trials

Recursion Pharmaceuticals Leaps 14% Ahead of Expected Early‑November Update

The AI‑drug developer with Nvidia backing draws Cramer’s skepticism, who says he needs proof of concept.